VTRS · 10-Q · 2026Q2 · Full report
Accrued Legal and Regulatory
Viatris Inc · 2026-08-06 · Importance 64 · Surprise 42 · In source text
Viatris had approximately $453 million accrued for legal contingencies at June 30, 2026, covering disputes, governmental and regulatory inquiries, investigations, tax proceedings, and litigation in the United States and abroad. The filing states that unfavorable outcomes could materially affect the Company’s business, financial condition, cash flows, dividends, share repurchases, or stock price. Under its Combination-related arrangements, Viatris generally assumed liabilities for Upjohn Business legal matters and agreed to indemnify Pfizer for those matters. Viatris also agreed to pay Pfizer 57% of certain opioid-related losses incurred since July 29, 2019; in June 2026, Pfizer requested information about payment, while Viatris disputed that the requested amount was owed.
Key facts
- Litigation settlements and other contingencies, net for the six months ended June 30, 2026 totaled $126.7 million, compared to $(121.1) million for the six months ended June 30, 2025; contingent consideration adjustment was $105.7 million and litigation settlements, net were $21.0 million for the six months ended June 30, 2026. source
- Litigation settlements and other contingencies, net for the three months ended June 30, 2026 totaled $73.2 million, compared to $(47.6) million for the three months ended June 30, 2025; contingent consideration adjustment was $21.3 million and litigation settlements, net were $51.9 million for the three months ended June 30, 2026. source
- The Company has approximately $453 million accrued for legal contingencies at June 30, 2026. source
- Viatris agreed to pay Pfizer an amount equal to 57% of any losses actually incurred or suffered by Viatris, its predecessors or subsidiaries, since July 29, 2019, arising out of third-party actions relating to the manufacture, distribution, marketing, promotion or sale of opioids by or on behalf of Viatris, its predecessors or subsidiaries. source
- In June 2026, the Company received a letter from Pfizer inquiring about the Company’s plan for payment to Pfizer under the foregoing agreement and the Company disagrees that the payment Pfizer requests is owed. source
- The Company believes it has certain insurance coverages for the Nashik losses, including for assets and business interruption. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| operating_income | negative | realized | -6.6% | Litigation settlements and other contingencies, net for the six months ended June 30, 2026 totaled $126.7 million, compared to $(121.1)… |
| liability | negative | realized | — | The Company has approximately $453 million accrued for legal contingencies at June 30, 2026. |
| liability | negative | contingent | — | Viatris agreed to pay Pfizer an amount equal to 57% of any losses actually incurred or suffered by Viatris, its predecessors or… |